Sign in
Taking people in United StatesPhase 4

Testosterone injections for men with low testosterone and early prostate cancer

Tests testosterone injections in men with low testosterone and early prostate cancer.

Key facts

Who runs it
University of Miami
Where
Miami, United StatesSee the 2 sites
Trial code
Registry title
Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
Status
Recruiting
Phase
Phase 4
People taking part
35 people, planned
Starts
30 Nov 2026
Expected to end
31 May 2032
Type of study
Interventional
Treatments tested
  • Testosterone cypionate
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with newly diagnosed low-risk prostate cancer on active surveillance who also have low testosterone and symptoms. It tests whether testosterone replacement is safe.

Age
18 years or older
Sex
Men only
Disease stage
Newly diagnosed low-risk prostate cancer, on active surveillance, confirmed by MRI-guided biopsy
Earlier treatment
No testosterone replacement therapy in the past year and not using it now
Biomarker or test result
Two testosterone levels below 350 ng/dL, taken before 10am, 24 hours to 90 days apart; symptom score (Aging Male's Symptoms Score) above 27

Main reasons for not taking part

  • Gleason score 7 (Grade Group 2) prostate cancer or higher
  • PSA above 10 ng/mL at the start
  • Hematocrit above 51% at the start
  • T3 or T4 disease
  • Unstable angina or a history of breast cancer

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Males aged ≥ 18 years old
  • Newly diagnosed with low-risk prostate cancer initially confirmed by fusion guided prostate biopsy (transrectal or trans perineal) by multiparametric MRI
  • Males diagnosed with low-risk prostate cancer on active surveillance
  • Two confirmatory testosterone levels <350 ng/dL (taken before 10am), with at least 24 hours and no more than 90 days between the two tests
  • Symptoms of low testosterone (Aging Male's Symptoms Score >27)
  • Able to obtain Testosterone medication through insurance or out-of-pocket
  • Willing and able to provide written informed consent and able to comply with study requirements

Who cannot take part

  • Unable or unwilling to obtain Testosterone medication through insurance or out-of-pocket
  • History of Testosterone Replacement Therapy (TRT) within the past year
  • Diagnosis of Gleason score 7 (Grade Group 2) prostate cancer or higher on diagnostic or confirmatory biopsy
  • T3 or T4 disease
  • Unstable angina
  • History of breast cancer
  • Any other condition or situation which, in the opinion of the investigator, could impact patient safety, prevent successful data collection, or reduce the likelihood of successful study participation
  • Males <18 years old
  • Current use of TRT
  • PSA >10 ng/mL at baseline
  • Hematocrit > 51% at baseline
  • Unable or unwilling to provide informed consent or comply with study requirements

Where in United States

  • Desai Sethi Urology InstituteMiami, United StatesContact: Thomas Masterson (principal investigator)Taking people
  • Sylvester Comprehensive Cancer Center*Miami, United StatesContact: Bruce Kava (principal investigator)Taking people

About the trial

What the trial wants to find out

The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on active surveillance.

The group in the trial

  • Testosterone cypionateTreatment being tested

    Participants will self-inject 100mg of testosterone cypionate once per week for 12 months

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Safety of Intramuscular Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
Plain-language title
Testosterone injections for men with low testosterone and early prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 November 2026